Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Karen Oestergaard Pedersen has worked on the following 4 EPO patent applications which have been published in the last five years:

EP10793244

GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS

IPC classification:
A61K 47/48, C07D 233/64, C07K 14/605
Applicant:
Novo Nordisk A/S
Agent:
Karen Oestergaard Pedersen, Novo Nordisk A/S
Status:
APPLICATION WITHDRAWN
EP11779456

DOUBLE-ACYLATED GLP-1 DERIVATIVES

IPC classification:
A61K 47/48, A61P 3/10, C07K 14/605
Applicant:
Novo Nordisk A/S
Agent:
Karen Oestergaard Pedersen, Novo Nordisk A/S
Status:
EXAMINATION IN PROGRESS
EP12805429

GLP-1 DERIVATIVES

IPC classification:
A61K 38/26, C07K 14/605
Applicant:
Novo Nordisk A/S
Agent:
Karen Oestergaard Pedersen, Novo Nordisk A/S
Status:
PATENT GRANTED
EP10788095

DOUBLE-ACYLATED GLP-1 DERIVATIVES

IPC classification:
A61K 47/48, C07K 14/605
Applicant:
Novo Nordisk A/S
Agent:
Karen Oestergaard Pedersen, Novo Nordisk A/S
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT

Please Sign in to use this feature